Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Beebe

Showing results (171-180 of 181) with videos related to

Pageof 19
Sort By:
International Journal of Nanomedicine|July 10, 2018
Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approachRyan M Kramer, Michelle C Archer, Mark T Orr, et al.
Cellular and Molecular Gastroenterology and Hepatology|October 16, 2023
GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent MannerKathleen R Smith, Wenshan Wang, Melissa R Miller, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.
Journal of Medicinal Chemistry|May 30, 2003
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-oneBanavara L Mylari, Sandra J Armento, David A Beebe, et al.
Journal of Medicinal Chemistry|September 30, 2005
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congenersBanavara L Mylari, Sandra J Armento, David A Beebe, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2009
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycleJeffrey A Pfefferkorn, Jihong Lou, Martha L Minich, et al.
Structure (London, England : 1993)|September 10, 2003
X-ray crystallographic and kinetic studies of human sorbitol dehydrogenaseThomas A Pauly, Jennifer L Ekstrom, David A Beebe, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2011
1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetesKim M Andrews, David A Beebe, John W Benbow, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 12, 2020
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model SystemsTrenton T Ross, Collin Crowley, Kenneth L Kelly, et al.
Journal of Medicinal Chemistry|August 29, 2013
Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structureDavid A Griffith, Robert L Dow, Kim Huard, et al.
Pageof 19

Showing results (171-180 of 181) with videos related to

Sort By:
Pageof 19
International Journal of Nanomedicine|July 10, 2018
Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approachRyan M Kramer, Michelle C Archer, Mark T Orr, et al.
Cellular and Molecular Gastroenterology and Hepatology|October 16, 2023
GPAT1 Deficiency in Mice Modulates NASH Progression in a Model-Dependent MannerKathleen R Smith, Wenshan Wang, Melissa R Miller, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 17, 2016
Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approachChristopher B Fox, Mark T Orr, Neal Van Hoeven, et al.
Journal of Medicinal Chemistry|May 30, 2003
A highly selective, non-hydantoin, non-carboxylic acid inhibitor of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran- 2-sulfonyl)-2-H-pyridazin-3-oneBanavara L Mylari, Sandra J Armento, David A Beebe, et al.
Journal of Medicinal Chemistry|September 30, 2005
A novel series of non-carboxylic acid, non-hydantoin inhibitors of aldose reductase with potent oral activity in diabetic rat models: 6-(5-chloro-3-methylbenzofuran-2-sulfonyl)-2H-pyridazin-3-one and congenersBanavara L Mylari, Sandra J Armento, David A Beebe, et al.
Bioorganic & Medicinal Chemistry Letters|May 14, 2009
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycleJeffrey A Pfefferkorn, Jihong Lou, Martha L Minich, et al.
Structure (London, England : 1993)|September 10, 2003
X-ray crystallographic and kinetic studies of human sorbitol dehydrogenaseThomas A Pauly, Jennifer L Ekstrom, David A Beebe, et al.
Bioorganic & Medicinal Chemistry Letters|February 18, 2011
1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetesKim M Andrews, David A Beebe, John W Benbow, et al.
Cellular and Molecular Gastroenterology and Hepatology|June 12, 2020
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model SystemsTrenton T Ross, Collin Crowley, Kenneth L Kelly, et al.
Journal of Medicinal Chemistry|August 29, 2013
Spirolactam-based acetyl-CoA carboxylase inhibitors: toward improved metabolic stability of a chromanone lead structureDavid A Griffith, Robert L Dow, Kim Huard, et al.
Pageof 19